Clinical trial
Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania
NCT00190892 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190892 |
|---|---|
| Title | Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania |
| Official title | Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | olanzapine, carbamazepine |
| Enrollment | 120 |
| Start date | Sep 1, 2004 |
| Completion | Jun 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | Australia, Greece, Hungary, Russia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: